Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
Garetosmab
FDA-approved in the US for the narrow adult FOP indication; metabolic and body-composition use remains investigational.
Apitegromab
An investigational antibody that inhibits myostatin activation, with a peer-reviewed Phase 2 trial showing less DXA-measured lean-mass loss during tirzepatide treatment, but no proven functional outcome in obesity.
How far human research has progressed
Garetosmab
US-approved for adult FOP after a controlled Phase 3 trial; metabolic/body-composition use remains investigationalApitegromab
Completed randomized, double-blind, placebo-controlled Phase 2 (EMBRAZE) in obesity; peer reviewed in Nature Medicine, 8 June 2026Claim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
Garetosmab
Controlled Phase 3 evidence supports the narrow adult-FOP indication. Obesity/body-composition evidence is limited to an earlier 26-week COURAGE combination arm and does not establish garetosmab as an obesity treatment.
Apitegromab
Controlled Phase 2 evidence supports less DXA-measured lean-mass loss during tirzepatide-associated weight loss over 24 weeks. DXA lean mass is not synonymous with skeletal muscle, and the trial does not establish better strength, mobility, frailty or long-term outcomes.
Human research context
Garetosmab
Adults with FOP in OPTIMA for the approved use; a separate 26-week COURAGE triplet arm in adults with obesity for investigational body composition.Apitegromab
102 adults with overweight or obesity receiving tirzepatide in EMBRAZE.Human efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Garetosmab
Apitegromab
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
Garetosmab
Apitegromab
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
Garetosmab
Apitegromab
Regulatory status (legal position, not proof it works)
Garetosmab
Named regulators: FDA (US)
FDA approved Pasatru (garetosmab-grts) on 19 August 2026 to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). That US approval is for FOP only. The European Medicines Agency review remains separate, and garetosmab is not approved for obesity, weight loss, lean-mass preservation or body composition.
Apitegromab
Check jurisdiction-specific details in the profile.
Not approved for any indication in our record. Obesity/body-composition use is investigational.
Common claims
Garetosmab
- · Reduces new heterotopic ossification lesions in adults with FOP
- · Reduces clinician-assessed FOP flare-ups
- · Improves weight loss or body composition in obesity
Apitegromab
- · Reduces lean-mass loss during GLP-1-based weight loss
- · Improves strength or prevents frailty in obesity
How settled our evidence rating is
Garetosmab
Apitegromab
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
Garetosmab
No established human cancer signal is identified in the cited approval materials. Longer post-marketing surveillance and indication-specific trial monitoring remain relevant.Apitegromab
No human cancer effect is established in our record.What this adds up to, in plain English
Garetosmab
Real controlled human trials exist, but questions about approval, how long benefits last, or long-term safety are still open.Apitegromab
Real controlled human trials exist, but questions about approval, how long benefits last, or long-term safety are still open.A comparison is not a recommendation